

# Can the FDA Salvage Interchangeable Follow-On Biologics?

PUBLICATIONS | LESS THAN 1 MIN READ

November 19, 2019


By: Ted Mathias

BioProcess Online / Biosimilar Development

*BioProcess Online* and *Biosimilar Development* published “Can the FDA Salvage Interchangeable Follow-On Biologics?”, an article co-written by Axinn partner Ted Mathias.

## Related People

---



Ted Mathias

To subscribe to our publications, [click here](#).

# Featured Insights

- American Bar Association 2025 Asia-Pacific Conference  
**SPEAKING ENGAGEMENT    ANTITRUST**
- NBA Commercial Law Section 38th Annual Corporate Counsel Conference  
**SPONSORSHIP    ANTITRUST**
- GCR Live: Law Leaders Global 2025  
**SPEAKING ENGAGEMENT    ANTITRUST**
- The 32nd Annual Marketing Partner Forum  
**EVENT**
- SABA North America Corporate Counsel Retreat 2025  
**SPONSORSHIP    ANTITRUST**
- Axinn Antitrust Insight: FTC Announces Revised HSR Thresholds for 2025  
**CLIENT ALERTS    ANTITRUST**
- Four Axinn Thought Leadership Pieces Nominated for the Antitrust Writing Awards  
**AWARDS & RECOGNITIONS    ANTITRUST**
- Merger Remedies Back in Vogue Under Trump  
**MEDIA MENTIONS    ANTITRUST**
- Three Takeaways from the Initial Determination at the ITC Regarding Standard Essential Patents in the 1380 Investigation  
**AXINN VIEWPOINTS    INTELLECTUAL PROPERTY**
- A POSA's Motivation Is Not Required To Be the Same as the Inventor's in Evaluating Obviousness  
**AXINN VIEWPOINTS    INTELLECTUAL PROPERTY**